ES2138122T3 - Polimeros como medios de contraste para resonancia magnetica. - Google Patents

Polimeros como medios de contraste para resonancia magnetica.

Info

Publication number
ES2138122T3
ES2138122T3 ES95111117T ES95111117T ES2138122T3 ES 2138122 T3 ES2138122 T3 ES 2138122T3 ES 95111117 T ES95111117 T ES 95111117T ES 95111117 T ES95111117 T ES 95111117T ES 2138122 T3 ES2138122 T3 ES 2138122T3
Authority
ES
Spain
Prior art keywords
magnetic resonance
polymers
contrast means
polymer
biocompatible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95111117T
Other languages
English (en)
Inventor
Evan C Unger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImaRx Pharmaceutical Corp
Original Assignee
ImaRx Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImaRx Pharmaceutical Corp filed Critical ImaRx Pharmaceutical Corp
Application granted granted Critical
Publication of ES2138122T3 publication Critical patent/ES2138122T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1803—Semi-solid preparations, e.g. ointments, gels, hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Signal Processing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Graft Or Block Polymers (AREA)

Abstract

LA INVENCION SE REFIERE A UN MEDIO DE CONTRASTE PARA LA FORMACION DE IMAGENES MEDIANTE RESONANCIA MAGNETICA QUE COMPRENDE, O CONSTA DE, UNA SOLUCION ACUOSA DE UNA SUSPENSION DE UN POLIMERO BIOCOMPATIBLE, NO ENLAZADO. EL POLIMERO PUEDE SER SINTETICO Y PUEDE COMPRENDER ADEMAS UN GAS BIOCOMPATIBLE.
ES95111117T 1990-04-10 1991-04-09 Polimeros como medios de contraste para resonancia magnetica. Expired - Lifetime ES2138122T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50712590A 1990-04-10 1990-04-10
EP91908011A EP0526503B1 (en) 1990-04-10 1991-04-09 Polymers as contrast media for magnetic resonance imaging

Publications (1)

Publication Number Publication Date
ES2138122T3 true ES2138122T3 (es) 2000-01-01

Family

ID=24017359

Family Applications (2)

Application Number Title Priority Date Filing Date
ES91908011T Expired - Lifetime ES2103809T3 (es) 1990-04-10 1991-04-09 Polimeros como medios de contraste para la formacion de imagenes por resonancia magnetica.
ES95111117T Expired - Lifetime ES2138122T3 (es) 1990-04-10 1991-04-09 Polimeros como medios de contraste para resonancia magnetica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES91908011T Expired - Lifetime ES2103809T3 (es) 1990-04-10 1991-04-09 Polimeros como medios de contraste para la formacion de imagenes por resonancia magnetica.

Country Status (8)

Country Link
EP (2) EP0693288B1 (es)
JP (1) JPH05506227A (es)
AT (2) ATE153860T1 (es)
DE (2) DE69131721T2 (es)
DK (1) DK0526503T3 (es)
ES (2) ES2103809T3 (es)
GR (1) GR3023806T3 (es)
WO (1) WO1991015753A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
WO1991018612A1 (en) * 1990-06-01 1991-12-12 Unger Evan C Contrast media for ultrasonic imaging
US5948387A (en) * 1990-06-01 1999-09-07 Imarx Pharmaceutical Corp. Contrast media for ultrasonic imaging
US5420176A (en) * 1990-06-01 1995-05-30 Imarx Pharmaceutical Corp. Contrast media for ultrasonic imaging
DE4117782C2 (de) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
CA2121681A1 (en) * 1991-11-19 1993-05-27 Evan C. Unger Gel particle contrast media for improved diagnostic imaging
US5514379A (en) * 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5323780A (en) * 1992-08-07 1994-06-28 University Of Florida Research Foundation, Inc. Artifact-free imaging contrast agent
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
AU5085793A (en) * 1992-09-04 1994-03-29 General Hospital Corporation, The Biocompatible polymers containing diagnostic or therapeutic moieties
WO1994008624A2 (en) * 1992-10-14 1994-04-28 Sterling Winthrop Inc. Therapeutic and diagnostic imaging compositions and methods
US5817292A (en) * 1992-10-14 1998-10-06 Nycomed Imaging As MR imaging compositions and methods
US5756688A (en) * 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
ES2105332T3 (es) * 1992-10-14 1997-10-16 Nycomed Imaging As Polimeros quelantes.
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
DK0783325T3 (da) * 1994-09-27 2000-05-01 Nycomed Imaging As Kontrastmiddel
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
WO1999052564A1 (en) * 1998-04-09 1999-10-21 Nycomed Imaging A.S Method
DE19942278C2 (de) * 1999-09-04 2001-09-13 Messer Griesheim Gmbh Quantitative Bestimmung des Xenongehaltes in Flüssigkeiten mit Hilfe der NMR-Spektroskopie
BRPI0619436A2 (pt) 2005-12-05 2011-10-04 Nitto Denko Corp métodos e conjugados de aminoácido-poliglutamato
WO2007132806A1 (ja) * 2006-05-17 2007-11-22 Otsuka Pharmaceutical Co., Ltd. ポリエチレングリコールを利用した磁気共鳴造影剤及び磁気共鳴撮像方法
US8197828B2 (en) 2007-05-09 2012-06-12 Nitto Denko Corporation Compositions that include a hydrophobic compound and a polyamino acid conjugate
KR101303567B1 (ko) * 2011-03-08 2013-09-23 주식회사 인트론바이오테크놀로지 카르복실기가 도입된 만난으로 코팅된 자기공명영상 조영제 및 그것의 제조 방법
CN107206111B (zh) 2014-12-31 2021-04-27 蓝瑟斯医学影像公司 脂质封装的气体微球组合物及相关方法
CN109641068B (zh) 2016-05-04 2022-09-30 蓝瑟斯医学影像公司 用于制备超声波造影剂的方法及装置
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069306A (en) * 1974-03-14 1978-01-17 Pharmacia Aktiebolag X-ray contrast preparation containing a hydrophilic polymer containing amino groups
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
US4775522A (en) * 1983-03-04 1988-10-04 Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center NMR compositions for indirectly detecting a dissolved gas in an animal
DE3316703A1 (de) * 1983-05-04 1984-11-08 Schering AG, 1000 Berlin und 4709 Bergkamen Orales kontrastmittel fuer die kernspintomographie und dessen herstellung
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
EP0184899B1 (en) * 1984-11-01 1990-04-18 Nycomed As Paramagnetic contrast agents for use in "in vivo" diagnostic methods using nmr, and their preparation
US4849210A (en) * 1985-05-08 1989-07-18 Molecular Biosystems, Inc. Magnetic resonance imaging of liver and spleen with superparamagnetic contrast agents
JPS62153229A (ja) * 1985-12-27 1987-07-08 Nippon Oil Co Ltd 皮膚マ−カ−
US4871716A (en) * 1986-02-04 1989-10-03 University Of Florida Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4729892A (en) * 1986-03-21 1988-03-08 Ciba-Geigy Corporation Use of cross-linked hydrogel materials as image contrast agents in proton nuclear magnetic resonance tomography and tissue phantom kits containing such materials
US4933441A (en) * 1987-01-27 1990-06-12 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
US4838274A (en) * 1987-09-18 1989-06-13 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance imaging
GB8813425D0 (en) * 1988-06-07 1988-07-13 Hall L D Magnetic resonance imaging
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US4996041A (en) * 1988-08-19 1991-02-26 Toshiyuki Arai Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system
GB8916780D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions

Also Published As

Publication number Publication date
ES2103809T3 (es) 1997-10-01
WO1991015753A1 (en) 1991-10-17
DE69126429D1 (de) 1997-07-10
EP0526503A1 (en) 1993-02-10
DE69126429T2 (de) 1997-10-23
EP0526503B1 (en) 1997-06-04
ATE185489T1 (de) 1999-10-15
EP0693288A1 (en) 1996-01-24
EP0526503A4 (en) 1993-02-24
JPH05506227A (ja) 1993-09-16
EP0693288B1 (en) 1999-10-13
ATE153860T1 (de) 1997-06-15
DK0526503T3 (da) 1997-10-27
DE69131721D1 (de) 1999-11-18
DE69131721T2 (de) 2000-03-02
GR3023806T3 (en) 1997-09-30

Similar Documents

Publication Publication Date Title
ES2138122T3 (es) Polimeros como medios de contraste para resonancia magnetica.
ATE201217T1 (de) Gasgefüllte mikrospheren enthaltende kontrastmittel zur diagnostischen bilderzeugung
DE69132930D1 (de) Poröse absorbierende polymermakrostrukturen und verfahren zur herstellung derselben
DE59005714D1 (de) Verfahren zur Herstellung wässriger Polymerisatdispersionen.
DE69023200D1 (de) Abstimmbarer resonanzverstärker.
ATE160940T1 (de) Kontrastmittel für ultraschallabbildung
DE68908114D1 (de) Implantierbares system fuer eine kuenstliche harnblase.
DE69707607D1 (de) Enzymbehandeltes Hesperidin, Verfahren zur Herstellung und Verfahren zur Verwendung von enzymbehandeltem Hesperidin
DE69001946D1 (de) Hoehenregulierung bei einem aktiven federungssystem.
DE69112149D1 (de) Durchlässige biokompatible Membran.
DE68904582D1 (de) Elektroakoustische membran und verfahren zur herstellung.
DE69001882D1 (de) Vorrichtung zur fahrzeugaufhaengung.
DE69106793D1 (de) Vorrichtung zur Aufhängungsregelung.
SE9300655D0 (sv) Kateter
DE69003771D1 (de) Verfahren zur Herstellung Mangandioxydkatalysators zur Hydrierung von Cyanhydrinen.
DE69012304D1 (de) Einrichtung zur Augenbehandlung.
DE69115278D1 (de) Herstellungsverfahren ringförmiger teile.
DE69104815D1 (de) Gaslaser-Oszillationsvorrichtung und Methode zur Justierung seiner optischen Achse.
DE59107953D1 (de) Verwendung von wässrigen Polymerisatdispersionen
NL189136B (nl) Polymeersuspensie, werkwijze ter bereiding daarvan alsmede toepassing daarvan.
DE3865794D1 (de) Hydroraffinationskatalysator, ausgehend von hydrogelen, verfahren zur herstellung und verwendung.
DE59008442D1 (de) Kleinmotor, Verfahren zur Herstellung desselben und Verwendung desselben.
DE69013700D1 (de) Optische Trägerplatte, optisches Informationsspeichermedium und Verfahren zur Herstellung der optischen Trägerplatte.
DE59104649D1 (de) Verfahren zur Herstellung von N,N,N',N'-Tetraglycidyl-3,3'-dialkyl-4,4'-diaminodiphenylmethanen.
DE58907891D1 (de) Verfahren zur Sterilisation von intraocularen Linsen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 693288

Country of ref document: ES